{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:49:51Z","timestamp":1791298191036,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"vor","delay-in-days":366,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.cmi.2015.05.038","type":"journal-article","created":{"date-parts":[[2015,6,6]],"date-time":"2015-06-06T22:56:56Z","timestamp":1433631416000},"page":"834-841","source":"Crossref","is-referenced-by-count":17,"title":["How to best measure the effectiveness of male human papillomavirus vaccine programmes?"],"prefix":"10.1016","volume":"21","author":[{"given":"S.M.","family":"Garland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.G.","family":"Molesworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.A.","family":"Machalek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Cornall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepehr N.","family":"Tabrizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl.\u00a05","key":"10.1016\/j.cmi.2015.05.038_bib1","doi-asserted-by":"crossref","first-page":"F12","DOI":"10.1016\/j.vaccine.2012.07.055","article-title":"Global burden of human papillomavirus and related diseases","volume":"30","author":"Forman","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2015.05.038_bib2","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia","volume":"365","author":"Palefsky","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2015.05.038_bib3","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males","volume":"364","author":"Giuliano","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2015.05.038_bib4","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/infdis\/jir287","article-title":"Population effectiveness, not efficacy, should decide who gets vaccinated against human papillomavirus via publicly funded programs","volume":"204","author":"Castle","year":"2011","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2015.05.038_bib5","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2015.05.038_bib6","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1016\/j.vaccine.2008.07.002","article-title":"Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica","volume":"26","author":"Herrero","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2015.05.038_bib7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2015.05.038_bib8","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","author":"The Future II Study Group","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"9679","key":"10.1016\/j.cmi.2015.05.038_bib9","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(09)60691-7","article-title":"Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24\u201345 years: a randomised, double-blind trial","volume":"373","author":"Mu\u00f1oz","year":"2009","journal-title":"Lancet"},{"issue":"9961","key":"10.1016\/j.cmi.2015.05.038_bib10","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(14)60920-X","article-title":"Efficacy, safety, and immunogenicity of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study","volume":"384","author":"Skinner","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2015.05.038_bib11","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(14)71073-4","article-title":"Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis","volume":"15","author":"Drolet","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2015.05.038_bib12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/1741-7015-11-227","article-title":"Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study","volume":"11","author":"Gertig","year":"2013","journal-title":"BMC Med"},{"issue":"3","key":"10.1016\/j.cmi.2015.05.038_bib13","doi-asserted-by":"crossref","first-page":"djt460","DOI":"10.1093\/jnci\/djt460","article-title":"Early Impact of Human Papillomavirus Vaccination on Cervical Neoplasia\u2014Nationwide Follow-up of Young Danish Women","volume":"106","author":"Baldur-Felskov","year":"2014","journal-title":"J\u00a0Natl Cancer I"},{"key":"10.1016\/j.cmi.2015.05.038_bib14","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/bjc.2014.479","article-title":"Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland","volume":"111","author":"Pollock","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cmi.2015.05.038_bib15","doi-asserted-by":"crossref","first-page":"f2032","DOI":"10.1136\/bmj.f2032","article-title":"Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data","volume":"346","author":"Ali","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2015.05.038_bib16","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/infdis\/jit361","article-title":"Declining genital Warts in young women in England associated with HPV 16\/18 vaccination: an ecological study","volume":"208","author":"Howell-Jones","year":"2013","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2015.05.038_bib17","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/infdis\/jit360","article-title":"Efficacy of the HPV-16\/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation","volume":"208","author":"Szarewski","year":"2013","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2015.05.038_bib18","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A\u00a09-Valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2015.05.038_bib19","series-title":"FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV [press release]","year":"2014"},{"key":"10.1016\/j.cmi.2015.05.038_bib20","series-title":"Notice of Compliance: Gardasil 9 [press release]","year":"2015"},{"key":"10.1016\/j.cmi.2015.05.038_bib21","first-page":"300","article-title":"Use of 9-valent human papillomavirus (hpv) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices","volume":"64","author":"Petrosky","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"RR-05","key":"10.1016\/j.cmi.2015.05.038_bib22","first-page":"1","article-title":"Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Markowitz","year":"2014","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.cmi.2015.05.038_bib23","first-page":"733","article-title":"National, state, and local area vaccination coverage among children aged 19\u201335 months\u2014United States, 2012","volume":"62","author":"Centers for Disease C, Prevention","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.cmi.2015.05.038_bib24","unstructured":"National HPV Vaccination Program Register. Preliminary estimates of HPV vaccination coverage for males\u2014school based program, first year of program delivery (2013) 2015 [27 April 2015]. Available from: http:\/\/www.hpvregister.org.au\/research\/coverage-data\/preliminary-estimates-male-hpv-coverage-2013."},{"key":"10.1016\/j.cmi.2015.05.038_bib25","doi-asserted-by":"crossref","first-page":"e101048","DOI":"10.1371\/journal.pone.0101048","article-title":"Incremental benefits of male HPV vaccination: accounting for inequality in population uptake","volume":"9","author":"Smith","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2015.05.038_bib26","unstructured":"UK Joint Committee on Vaccination and Immunisation. Interim position statement on HPV vaccination of men who have sex with men (MSM) November 2014 [22 May 2015]. Available from: https:\/\/www.gov.uk\/government\/publications\/interim-statement-on-hpv-vaccination-of-men-who-have-sex-with-men."},{"key":"10.1016\/j.cmi.2015.05.038_bib27","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.vaccine.2014.10.047","article-title":"The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines","volume":"33","author":"Lopalco","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2015.05.038_bib28","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1071\/SH09137","article-title":"Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: towards a national HPV surveillance strategy","volume":"7","author":"Brotherton","year":"2010","journal-title":"Sex Health"},{"key":"10.1016\/j.cmi.2015.05.038_bib29","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/sextrans-2014-051813","article-title":"Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme","volume":"91","author":"Chow","year":"2015","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.cmi.2015.05.038_bib30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/sti.2010.044412","article-title":"Different population-level vaccination effectiveness for HPV types 16, 18, 6 and 11","volume":"87","author":"Brisson","year":"2011","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.cmi.2015.05.038_bib31","unstructured":"Bruni L, Barrionuevo-Rosas L, Albero G, Aldea M, Serrano B, Valencia S, et al. ICO Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in the World. Summary Report 2015-04-08. [Data Accessed]."},{"key":"10.1016\/j.cmi.2015.05.038_bib32","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1086\/507432","article-title":"Prevalence of HPV infection among men: a systematic review of the literature","volume":"194","author":"Dunne","year":"2006","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2015.05.038_bib33","first-page":"2630","article-title":"Prevalence of genital human papillomavirus among men in Europe: systematic review and meta-analysis","volume":"11","author":"Hebnes","year":"2014","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.cmi.2015.05.038_bib34","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/sextrans-2013-051456","article-title":"Human papillomavirus prevalence among men in sub-Saharan Africa: a systematic review and meta-analysis","volume":"90","author":"Olesen","year":"2014","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.cmi.2015.05.038_bib35","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jadohealth.2011.03.010","article-title":"Age-specific prevalence of human papillomavirus infection in males: a global review","volume":"48","author":"Smith","year":"2011","journal-title":"J\u00a0Adolesc Health"},{"key":"10.1016\/j.cmi.2015.05.038_bib36","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1097\/OLQ.0b013e31822154f9","article-title":"The prevalence of genital HPV and factors associated with oncogenic HPV among men having sex with men and men having sex with women and men: the HIM study","volume":"38","author":"Nyitray","year":"2011","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.cmi.2015.05.038_bib37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/infdis\/jiq021","article-title":"Age-specific prevalence of and risk factors for anal human papillomavirus (HPV) among men who have sex with women and men who have sex with men: the HPV in men (HIM) study","volume":"203","author":"Nyitray","year":"2011","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2015.05.038_bib38","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1093\/infdis\/jiq015","article-title":"External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continents","volume":"203","author":"Vardas","year":"2011","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2015.05.038_bib39","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/infdis\/jiq016","article-title":"Prevalence of and risk factors for human papillomavirus (HPV) infection among HIV-seronegative men who have sex with men","volume":"203","author":"Goldstone","year":"2011","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2015.05.038_bib40","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/infdis\/jiu077","article-title":"Incidence, clearance, and disease progression of genital human papillomavirus infection in heterosexual men","volume":"210","author":"Moreira","year":"2014","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2015.05.038_bib41","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S1473-3099(14)70841-2","article-title":"Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study","volume":"14","author":"Tabrizi","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2015.05.038_bib42","first-page":"319","article-title":"A\u00a0new national Chlamydia Sentinel Surveillance System in Australia: evaluation of the first stage of implementation","volume":"34","author":"Guy","year":"2010","journal-title":"Commun Dis Intell Q Rep"},{"issue":"8","key":"10.1016\/j.cmi.2015.05.038_bib43","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1086\/521629","article-title":"The optimal anatomic sites for sampling heterosexual men for human papillomavirus (HPV) detection: the HPV Detection in Men Study","volume":"196","author":"Giuliano","year":"2007","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2015.05.038_bib44","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1002\/jmv.22183","article-title":"Urine testing as a surveillance tool to monitor theimpact of HPV immunization programs","volume":"83","author":"Cuschieri","year":"2011","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.cmi.2015.05.038_bib45","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/jmv.22167","article-title":"Human papillomavirus genotype detection and viral load in paired genital and urine samples from both females and males","volume":"83","author":"Bissett","year":"2011","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.cmi.2015.05.038_bib46","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/infdis\/jit626","article-title":"Early acquisition of anogenital human papillomavirus among teenage men who have sex with men","volume":"209","author":"Zou","year":"2014","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2015.05.038_bib47","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1473-3099(14)70994-6","article-title":"Site-specific human papillomavirus infection in adolescent men who have sex with men (HYPER): an observational cohort study","volume":"15","author":"Zou","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2015.05.038_bib48","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jviromet.2007.12.010","article-title":"Reliability of sample collection and laboratory testing for HPV detection in men","volume":"149","author":"Flores","year":"2008","journal-title":"J\u00a0Virol Methods"},{"key":"10.1016\/j.cmi.2015.05.038_bib49","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jcv.2013.06.032","article-title":"Evaluation of genital self-sampling methods for HPV detection in males","volume":"58","author":"Hernandez","year":"2013","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.cmi.2015.05.038_bib50","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1136\/sti.2008.033068","article-title":"Self-collection of genital human papillomavirus specimens in heterosexual men","volume":"85","author":"Ogilvie","year":"2009","journal-title":"Sex Transm Infect"},{"issue":"3","key":"10.1016\/j.cmi.2015.05.038_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092208","article-title":"Anal, penile, and oral high-risk HPV infections and HPV seropositivity in HIV-positive and HIV-negative men who have sex with men","volume":"9","author":"van Rijn","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2015.05.038_bib52","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/00126334-200408010-00004","article-title":"Self-collected versus clinician-collected anal cytology specimens to diagnose anal intraepithelial neoplasia in HIV-positive men","volume":"36","author":"Cranston","year":"2004","journal-title":"J\u00a0Acq Immun Def Synd"},{"key":"10.1016\/j.cmi.2015.05.038_bib53","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/00007435-199611000-00010","article-title":"Patient-administered tampon-collected genital cells in the assessment of Chlamydia trachomatis infection using polymerase chain reaction","volume":"23","author":"Tabrizi","year":"1996","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.cmi.2015.05.038_bib54","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1128\/JCM.02105-12","article-title":"Comparison of hybrid capture II, linear array, and a bead-based multiplex genotyping assay for detection of human papillomavirus in women with negative Pap test results and atypical squamous cells of undetermined significance","volume":"50","author":"Comar","year":"2012","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2015.05.038_bib55","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1128\/JCM.01064-12","article-title":"Comparison of PapType to Digene Hybrid Capture 2, Roche Linear Array, and Amplicor for detection of high-risk human papillomavirus genotypes in women with previous abnormal Pap smears","volume":"50","author":"Tabrizi","year":"2012","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2015.05.038_bib56","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jviromet.2014.12.007","article-title":"In\u00a0vitro assessment of the effect of vaccine-targeted human papillomavirus (HPV) depletion on detection of non-vaccine HPV types: Implications for post-vaccine surveillance studies","volume":"214","author":"Cornall","year":"2015","journal-title":"J\u00a0Virol Methods"},{"key":"10.1016\/j.cmi.2015.05.038_bib57","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1128\/JCM.02453-13","article-title":"Global improvement in genotyping of human papillomavirus DNA: the 2011 HPV LabNet International Proficiency Study","volume":"52","author":"Eklund","year":"2014","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2015.05.038_bib58","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1158\/1055-9965.EPI-14-0566","article-title":"Evaluation of human papillomavirus type replacement postvaccination must account for diagnostic artifacts: masking of HPV52 by HPV16 in anogenital specimens","volume":"24","author":"Tota","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.cmi.2015.05.038_bib59","first-page":"32","article-title":"Impact of coverage-dependent marginal costs on optimal HPV vaccination strategies","volume":"11","author":"Ryser","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2015.05.038_bib60","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/infdis\/jir285","article-title":"Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity","volume":"204","author":"Brisson","year":"2011","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2015.05.038_bib61","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1086\/587895","article-title":"Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia","volume":"46","author":"Newall","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2015.05.038_bib62","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/jmv.23616","article-title":"Review: current knowledge on the role of HPV antibodies after natural infection and vaccination: implications for monitoring an HPV vaccination programme","volume":"85","author":"Mollers","year":"2013","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.cmi.2015.05.038_bib63","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0065-230X(01)82007-8","article-title":"Immunity to oncogenic human papillomaviruses","volume":"82","author":"Konya","year":"2001","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.cmi.2015.05.038_bib64","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/jnci\/89.9.630","article-title":"Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia","volume":"89","author":"de Gruijl","year":"1997","journal-title":"J\u00a0Natl Cancer I"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X15005704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X15005704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,22]],"date-time":"2018-09-22T01:58:25Z","timestamp":1537581505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X15005704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":64,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S1198743X15005704"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2015.05.038","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}